Quirós Carmen, Patrascioiu Ioana, Mora Mireia, Aranda Gloria Beatriz, Hanzu Felicia Alexandra, Gómez-Gil Esther, Godás Teresa, Halperin Irene
Endocrinology Unit, Hospital Clinic i Universitari de Barcelona, Spain.
Endocrinology Unit, Hospital Clinic i Universitari de Barcelona, Spain.
Endocrinol Nutr. 2015 May;62(5):210-6. doi: 10.1016/j.endonu.2015.02.001. Epub 2015 Mar 16.
Since the onset of cross hormone therapy (CHT) in transsexual individuals, there has been concern about possible chronic side effects. Our objective was to assess baseline differences in lipid profile in individuals with gender identity disorder in relation to prior CHT, and changes in the lipid profile and other cardiovascular (CV) risk factors after 24 months of treatment.
Retrospective longitudinal study including all individuals assisted for the first time in the Gender Identity Unit of Catalonia from 2006 to 2010. Socio-demographical, anthropometric and laboratory data were collected.
We evaluated 247 transsexuals, 150 male to female (MtF: 60.7%) and 97 female to male (FtM; 39.3%). At baseline, FtM transsexuals were younger and had started prior CHT less often than MtF (13.4% vs. 64.7%; p<0.001). During follow up, in MtF weight and BMI increased significantly, as well as systolic and diastolic blood pressure, though these latter remained within normal range. No significant differences in lipid profile were observed. FtM transsexuals also presented an increase in weight and BMI, without differences in blood pressure. A general worsening in lipid profile was observed in this group, with increased total cholesterol (166.0 ± 35.1 vs. 175.6 ± 38.2mg/dL; p=0.001), triglycerides (70.6 ± 30.7 vs. 102.3 ± 68.5 mg/dL; p<0.001) and LDL cholesterol (103.8 ± 28.7 vs. 112.8 ± 30.3 mg/dL; p=.013) and decreased HDL cholesterol (52.2 ± 12.2 vs. 45.4 ± 13.8 mg/dL; p=0.001), even though final levels were all within normal range.
There is no detectable increase in CV risk factors in MtF transsexuals who were treated with currently prescribed estrogenic compounds, while a slight worsening in lipid profile takes place in the FtM group, though within normal limits.
自变性者开始接受跨性别激素治疗（CHT）以来，人们一直担心可能出现的慢性副作用。我们的目的是评估性别认同障碍患者与既往CHT相关的血脂谱基线差异，以及治疗24个月后血脂谱和其他心血管（CV）危险因素的变化。
回顾性纵向研究，纳入2006年至2010年首次在加泰罗尼亚性别认同科接受治疗的所有患者。收集社会人口统计学、人体测量学和实验室数据。
我们评估了247名变性者，其中150名男性变女性（MtF：60.7%），97名女性变男性（FtM：39.3%）。基线时，FtM变性者比MtF更年轻，且较少开始接受既往CHT（13.4%对64.7%；p<0.001）。随访期间，MtF的体重和BMI显著增加，收缩压和舒张压也升高，尽管后者仍在正常范围内。血脂谱未观察到显著差异。FtM变性者的体重和BMI也有所增加，血压无差异。该组血脂谱普遍恶化，总胆固醇升高（166.0±35.1对175.6±38.2mg/dL；p=0.001）、甘油三酯升高（70.6±30.7对102.3±68.5mg/dL；p<0.001）、低密度脂蛋白胆固醇升高（103.8±28.7对112.8±30.3mg/dL；p=0.013），高密度脂蛋白胆固醇降低（52.2±12.2对45.4±13.8mg/dL；p=0.001），尽管最终水平均在正常范围内。
接受目前规定的雌激素化合物治疗的MtF变性者，心血管危险因素未发现可检测到的增加，而FtM组血脂谱略有恶化，但仍在正常范围内。
